KCT0003425已完成未知
Open label, multicenter, prospective phase II study to investigate the efficacy and safety of Trastuzumab biosimilar (Herzuma®) plus treatment of physician’s choice (TPC) in Patients with HER-2 Positive Metastatic Breast Cancer Who Progressed after 2 or more HER-2 directed Chemotherapy
ational Cancer Center0 个研究点目标入组 128 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 128
研究概览
简要总结
Treatment of HER2-positive breast cancer is rapidly evolving with the development of new agents. However, treatment options are still limited after progression with proven anti-HER2 therapies. • The combination of chemotherapy with a trastuzumab biosimilar, Herzuma®, was effective and safe in patients with heavily pre-treated HER2+ MBC. • Duration of response to previous anti-HER2 therapy, PIK3CA and ERBB2 mutations were associated with clinical efficacies of trastuzumab biosimilar plus chemotherapy.
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Patient is an adult, = 19 years old at the time of informed consent.
- •2) Patient has histologically and/or cytologically confirmed diagnosis of HER2-positive breast cancer (HER-2/neu 3+ as defined by immunohistochemistry and/or HER-2/neu gene amplification as defined by fluorescence in situ hybridization).
- •3) Metastatic or unresectable disease documented on diagnostic imaging studies.
- •4) Prior 2 or more HER-2 directed therapy for metastatic disease is mandatory.
- •5) Patient must have at least one measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
- •6) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- •7) Adequate bone marrow and organ function including:
- •a) WBC(White Blood Cell) = 3500/ml;
- •b) Platelets = 100,000/ul;
- •c) Hemoglobin >9.0 g/dl;
- •d) Total bilirubin = 1.5x ULN;
- •e) AST and ALT < 2.5 x ULN;
- •f) Alkaline phosphatase <2.5x ULN;
- •g) Creatinine = 1.5x ULN or CCr >60 ml/min for patients with abnormal serum Cr level function.
- •8) Life expectance longer than 3 months
- •9) Patient has an adequate left ventricular ejection function of at least 50 % at baseline, as measured by echocardiography.
- •10) Written informed consent
排除标准
- •1) Patient is pregnant or lactating, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
- •2) Patient has symptomatic and unstable CNS(central nervous system) metastases, except for treated brain metastases. Treated brain metastases are defined as having no evidence of progression or hemorrhage after treatment and no ongoing requirement for dexamethasone, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period. Anticonvulsants (stable dose) are allowed.
- •3) Active and clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus syndrome (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness. Baseline viral assessment is not required in patients with no known infection.
- •4) Major surgery within 4 weeks of first dose of investigational product or not fully recovered from any side effects of previous procedures.
- •5) Any other malignancy within 3 years prior to first dose of investigational product except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
- •6) QTc(Corrected QT Interval) interval >480 msec (based on the mean value of the triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc(Corrected QT Interval) prolongation or Torsade de Pointes.
- •7) Any of the following within 6 months of first dose of investigational product myocardial infarction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE(Common Terminology Criteria for Adverse Events) v. 5.0 Grade =2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism.
- •8) History of symptomatic interstitial pneumonitis.
- •9) Patients with a history of hypersensitivity reactions to trastuzumab, rodent-derived proteins, or components of trastuzumab
- •10) Other severe acute or chronic medical or psychiatric condition, including recent (within the past year) or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
研究者
相似试验
招募中
2 期
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06760819Bayer111
招募中
3 期
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerNCT06255392Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University200
撤回
1 期
A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsGastroesophageal Junction AdenocarcinomaBreast CancerGastric CancerNCT05678205Artiva Biotherapeutics, Inc.133
已完成
2 期
Trastuzumab & Pertuzumab Followed by T-DM1 in MBCMetastatic Breast CancerNCT01835236Swiss Group for Clinical Cancer Research208
已完成
2 期
Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast CancerHER2-positive Breast CancerMetastatic Breast CancerNCT03755141National Cancer Center, Korea109